Krka d. d (KRK) - Net Assets

Latest as of June 2026: zł2.64 Billion PLN ≈ $726.57 Million USD

Based on the latest financial reports, Krka d. d (KRK) has net assets worth zł2.64 Billion PLN (≈ $726.57 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł3.34 Billion ≈ $918.05 Million USD) and total liabilities (zł695.76 Million ≈ $191.48 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Krka d. d's equity deployed to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets zł2.64 Billion
% of Total Assets 79.14%
Annual Growth Rate 5.58%
5-Year Change 23.93%
10-Year Change 64.65%
Growth Volatility 3.05

Krka d. d - Net Assets Trend (2010–2025)

This chart illustrates how Krka d. d's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Krka d. d worth.

Annual Net Assets for Krka d. d (2010–2025)

The table below shows the annual net assets of Krka d. d from 2010 to 2025. Also explore KRK net asset momentum to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2025-12-31 zł2.38 Billion
≈ $654.54 Million
+6.28%
2024-12-31 zł2.24 Billion
≈ $615.87 Million
+2.57%
2023-12-31 zł2.18 Billion
≈ $600.45 Million
+2.02%
2022-12-31 zł2.14 Billion
≈ $588.55 Million
+11.43%
2021-12-31 zł1.92 Billion
≈ $528.16 Million
+9.55%
2020-12-31 zł1.75 Billion
≈ $482.12 Million
+5.06%
2019-12-31 zł1.67 Billion
≈ $458.92 Million
+8.26%
2018-12-31 zł1.54 Billion
≈ $423.90 Million
+3.53%
2017-12-31 zł1.49 Billion
≈ $409.44 Million
+2.99%
2016-12-31 zł1.44 Billion
≈ $397.53 Million
+2.74%
2015-12-31 zł1.41 Billion
≈ $386.95 Million
+4.00%
2014-12-31 zł1.35 Billion
≈ $372.06 Million
+1.45%
2013-12-31 zł1.33 Billion
≈ $366.75 Million
+7.42%
2012-12-31 zł1.24 Billion
≈ $341.41 Million
+8.84%
2011-12-31 zł1.14 Billion
≈ $313.68 Million
+8.21%
2010-12-31 zł1.05 Billion
≈ $289.89 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Krka d. d's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 29.7% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings zł601.09 Million 25.47%
Common Stock zł54.76 Million 2.32%
Other Comprehensive Income zł143.19 Million 6.07%
Other Components zł1.56 Billion 66.14%
Total Equity zł2.36 Billion 100.00%

Krka d. d Competitors by Market Cap

The table below lists competitors of Krka d. d ranked by their market capitalization.

Company Market Cap
Grupo Aeroportuario del Pacífico S.A.B. de C.V
MX:GAPB
$9.47 Billion
China Merchants Shekou Industrial Zone Holdings
SHE:001979
$9.47 Billion
Guangzhou Tinci Materials Technology Co Ltd
SHE:002709
$9.47 Billion
Empresas Copec S.A.
SN:COPEC
$9.48 Billion
UNITED UTILITIES GP ADR/2
F:UUEA
$9.46 Billion
Beijing YanDong MicroElectronic Co. Ltd. A
SHG:688172
$9.46 Billion
Orkla ASA
OL:ORK
$9.45 Billion
Addtech AB (publ.)
ST:ADDT-B
$9.45 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Krka d. d's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 2,218,183,000 to 2,359,799,785, a change of 141,616,785 (6.4%).
  • Net income of 403,432,225 contributed positively to equity growth.
  • Dividend payments of 252,084,611 reduced retained earnings.
  • Share repurchases of 61,585,954 reduced equity.
  • Other comprehensive income increased equity by 157,766,648.
  • Other factors decreased equity by 105,911,523.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income zł403.43 Million +17.1%
Dividends Paid zł252.08 Million -10.68%
Share Repurchases zł61.59 Million -2.61%
Other Comprehensive Income zł157.77 Million +6.69%
Other Changes zł-105.91 Million -4.49%
Total Change zł- 6.38%

Book Value vs Market Value Analysis

This analysis compares Krka d. d's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 14.99x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 36.50x to 14.99x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2010-12-31 zł31.12 zł1136.00 x
2011-12-31 zł33.89 zł1136.00 x
2012-12-31 zł37.23 zł1136.00 x
2013-12-31 zł40.34 zł1136.00 x
2014-12-31 zł41.22 zł1136.00 x
2015-12-31 zł43.16 zł1136.00 x
2016-12-31 zł44.54 zł1136.00 x
2017-12-31 zł46.15 zł1136.00 x
2018-12-31 zł48.04 zł1136.00 x
2019-12-31 zł52.41 zł1136.00 x
2020-12-31 zł55.52 zł1136.00 x
2021-12-31 zł61.09 zł1136.00 x
2022-12-31 zł68.19 zł1136.00 x
2023-12-31 zł69.85 zł1136.00 x
2024-12-31 zł72.06 zł1136.00 x
2025-12-31 zł75.79 zł1136.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Krka d. d utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 17.10%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 19.76%
  • • Asset Turnover: 0.67x
  • • Equity Multiplier: 1.29x
  • Recent ROE (17.10%) is above the historical average (13.86%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2010 16.26% 16.93% 0.68x 1.41x zł65.85 Million
2011 14.30% 15.14% 0.70x 1.35x zł48.98 Million
2012 12.91% 13.99% 0.70x 1.31x zł36.01 Million
2013 12.98% 14.39% 0.68x 1.32x zł39.71 Million
2014 12.31% 13.95% 0.66x 1.33x zł31.16 Million
2015 11.27% 13.59% 0.64x 1.29x zł17.77 Million
2016 7.51% 9.23% 0.61x 1.32x zł-35.89 Million
2017 10.26% 12.05% 0.66x 1.29x zł3.93 Million
2018 11.35% 13.11% 0.67x 1.29x zł20.83 Million
2019 14.75% 16.44% 0.68x 1.31x zł79.11 Million
2020 16.69% 18.96% 0.69x 1.28x zł116.66 Million
2021 16.23% 19.75% 0.62x 1.33x zł118.69 Million
2022 17.15% 21.15% 0.64x 1.27x zł151.43 Million
2023 14.52% 17.38% 0.65x 1.28x zł97.74 Million
2024 16.09% 18.69% 0.67x 1.28x zł135.17 Million
2025 17.10% 19.76% 0.67x 1.29x zł167.45 Million

Industry Comparison

This section compares Krka d. d's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $554,002,000
  • Average return on equity (ROE) among peers: -2.10%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Krka d. d (KRK) zł2.64 Billion 16.26% 0.26x $9.47 Billion
Celon Pharma SA (CLN) $554.00 Million -2.10% 0.28x $213.32 Million

About Krka d. d

WAR:KRK Poland Drug Manufacturers - Specialty & Generic
Market Cap
$9.47 Billion
zł34.39 Billion PLN
Market Cap Rank
#2322 Global
#12 in Poland
Share Price
zł1136.00
Change (1 day)
-0.18%
52-Week Range
zł806.00 - zł1198.00
All Time High
zł1198.00
About

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, an… Read more